Hosted on MSN7mon
Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers: StudyTAS102 plus regorafenib is a synergistic drug combination in preclinical models of GI cancer, with regorafenib suppressing TAS102-induced increase in microvessel density and p-ERK as contributing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback